Evaluation of Preoperative Chemotherapy Using PET with Fluorine-18-Fluorodeoxyglucose in Breast Cancer

Journal of Nuclear Medicine

Volumn 37, Issue 6, 1996, Pages 931-938

  Bassa, Pedro ^a   Edmund Kim, E ^a   Inoue, Tomio ^a   Wong, Franklin C L ^a   Korkmaz, Meliha ^a   Yang, David J ^a   Wong, Wai Hoi ^a   Hicks, Keri W ^a   Buzdar, Aman U ^a   Podoloff, Donald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Fluorine 18 fluorodeoxyglucose; PET; Preoperative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYGLUCOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOMAMMOGRAPHY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; ULTRASONOGRAPHY, MAMMARY;

EID: 0030163040     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer, principles and practice of oncology, 4th ed. Philadelphia: JB Lippincott Co.; 1993:1264-1324.
2. Donegan W. Cancer of the breast, 3rd ed. Philadelphia: WB Saunders; 1988:389.
3. Swain MS. Selection of therapy for stage III breast cancer. Surg Clin North Am 1990;70:1061-1080.
4. Hortobagyi GN, Ames FC, Buzdar AU. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 1988;62:2507-2516.
5. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992;69:2849-2852.
6. McCready DR, Hortobagyi GN, Kau SW, et al. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989;124:21-25.
7. Forstrom LA. Positron emission tomography - the promise of metabolic imaging. Mayo Clin Proc 1989;64:720-724.
8. Hawkins RA, Hoh C, Dahlbom M, et al. PET cancer evaluation with FDG. J Nucl Med 1991;32:1555-1558.
9. Hawkins RA, Phelps ME. PET in clinical oncology. Cancer Metastasis Rev 1988;7:119-142.
10. Sigurdson ER, Cohen AM. Commentary on "The applications of PET in clinical oncology" [Editorial]. J Nucl Med 1991;32:649-650.
11. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648.
12. 18F]-Fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-770.
13. 18F]2-Deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-750.
14. 18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989;13:1097-1098.
15. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992;216:27-34.
16. Nieweg OE, Kim EE, Wong W-H, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920-3925.
17. Whal RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-2111.
18. 18F]fluoro-2-deoxy-D-glucose. J Nucl Med 1995;36:788-793.
19. Mullani NA, Gould KL, Hartz RK, et al. Design and performance of Posicam 6.5 BGO positron camera. J Nucl Med 1990;31:610-616.
20. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847-850.
21. American Joint Commission on Cancer Staging and End-Results Reporting. Manual for staging of cancer, 2nd ed. Philadelphia: JB Lippincott Co.; 1983:127-133.
22. ICP Breast Cancer Task Force. Positron emission tomography. Clinical application and economic implications of PFT in the assessment of axillary lymph node involvement in breast cancer a prospective study [Abstract]. Proceedings of 1994 ICP Meeting. ICP Breast Cancer Task Force.
23. 18F-2-fluoro-2-deoxy-D-glucose. Eur J Nucl Med 1986;12:329-332.
24. 3H-deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med 1985;26:278-282.
25. 3H-thymidine uptake. J Nucl Med 1993;34:414-419.
26. Brown RS, Fisher SH, Wahl RL. Autoradiographic evaluation of the intra-tumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma. J Nucl Med 1993;34:75-82.
27. Minn H, Joensuu H, Ahonen A, et al: Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988;61:1776-1781.
28. 3H]thymidine and gallium-67. J Nucl Med 1991;32:2118-2123.
29. 18F]fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1986;22:360-371.
30. 3H] sugars by nonmalignant and malignant human breast. J Pathol 1986;149:173-181.